Evaluate the Efficacy and Safety of Reslizumab for Patients with Eosinophilic Asthma
- Study Title
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- Teva Identifier
- C38072/3081 | 2010-023342-67
- ClinicalTrials.gov Identifier
- NCT01270464
- Study Status
- Completed
- Trial Condition(s)
- Eosinophilic Asthma
- Interventions
- Drug: Reslizumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years to 75 Years
- Trial Duration
- 02/01/2011 - 09/01/2013
- Phase
- Phase 3
